Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by ScienceFirston Apr 26, 2023 10:26pm

197 Views

Post# 35416119

Another oncology blow for Roche

Roche is having problems finding an efficient oncology platform. It goes from one failure to another..

Maybe they will be more inclined to listen to the potential of our PDT/PDC plaftorm.

Note that Roche:

- voluntarily withdrew from the bladder cancer indication after failing its confirmatory trial following its Accelerated Approval designation
- has a presence in the 3 fields of expertise we're targetting; urology, neurology, pulmonary

Roche execs tightlipped on possible TIGIT fail

Roche executives have insisted that they haven’t given up on anti-TIGIT checkpoint inhibitors, even as they dodged questions about whether their candidate has flunked yet another phase 3 trial.

<< Previous

Bullboard Posts

Next >>

2024, a breakthrough year for silver